Pfizer Reaches New 52-Week High (PFE)

NEW YORK ( TheStreet) -- Pfizer (NYSE: PFE) hit a new 52-week high Wednesday as it is currently trading at $22.81, above its previous 52-week high of $22.80 with 1.3 million shares traded as of 9:35 a.m. ET. Average volume has been 35.1 million shares over the past 30 days.

Pfizer has a market cap of $168.69 billion and is part of the health care sector and drugs industry. Shares are up 4.6% year to date as of the close of trading on Tuesday.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 20.2, above the average drugs industry P/E ratio of 17.5 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Pfizer Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux